| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.LUNGCAN.2012.08.010 |
| P698 | PubMed publication ID | 22959242 |
| P50 | author | Susan S Jick | Q42946335 |
| P2093 | author name string | Christoph R Meier | |
| Claudia Becker | |||
| Michael Bodmer | |||
| P433 | issue | 2 | |
| P921 | main subject | metformin | Q19484 |
| lung cancer | Q47912 | ||
| P304 | page(s) | 133-137 | |
| P577 | publication date | 2012-09-07 | |
| P1433 | published in | Lung Cancer | Q641464 |
| P1476 | title | Metformin does not alter the risk of lung cancer: a case-control analysis | |
| P478 | volume | 78 |
| Q35200421 | Association of the metformin with the risk of lung cancer: a meta-analysis |
| Q38147841 | Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates |
| Q38858585 | Cancer risk of sulfonylureas in patients with type 2 diabetes mellitus: A systematic review |
| Q28386632 | Chemoprevention of lung cancer: prospects and disappointments in human clinical trials |
| Q36402823 | Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony |
| Q33748862 | Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis |
| Q38651175 | Diabetes drugs and the incidence of solid cancers: a survey of the current evidence. |
| Q37737183 | Effect of Metformin on Different Non-Diabetes Related Conditions, a Special Focus on Malignant Conditions: Review of Literature |
| Q34432841 | Effects of metformin on retinoblastoma growth in vitro and in vivo. |
| Q35803926 | Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis |
| Q46264190 | Geroprotectors as a therapeutic strategy for COPD - where are we now? |
| Q26995495 | Lung cancer chemoprevention: current status and future prospects |
| Q64226496 | Metformin Use and Lung Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis |
| Q38999875 | Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation |
| Q34135248 | Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders |
| Q41303279 | Metformin and lung cancer risk of patients with type 2 diabetes mellitus: A meta-analysis |
| Q42561182 | Metformin and the incidence of cancer in patients with diabetes: a nested case-control study |
| Q38128357 | Metformin in lung cancer: rationale for a combination therapy |
| Q35046673 | Metformin use and lung cancer risk in patients with diabetes. |
| Q38393435 | Metformin, an old drug, brings a new era to cancer therapy |
| Q39100209 | Metformin: New Preparations and Nonglycemic Benefits |
| Q33913626 | Modulation by metformin of molecular and histopathological alterations in the lung of cigarette smoke-exposed mice |
| Q35810943 | No evidence for a decreased risk of thyroid cancer in association with use of metformin or other antidiabetic drugs: a case-control study. |
| Q36505700 | Pharmacological Modulation of Lung Carcinogenesis in Smokers: Preclinical and Clinical Evidence |
| Q33688699 | Prognostic role of metformin intake in diabetic patients with colorectal cancer: An updated qualitative evidence of cohort studies |
| Q93148944 | Role of p53 Family Proteins in Metformin Anti-Cancer Activities |
| Q35153493 | Survival of patients with stage IV lung cancer with diabetes treated with metformin |
| Q41339882 | Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials |
| Q35038355 | Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. |
| Q33645356 | Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activation |
Search more.